Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next
Author: tennjed33 Big gold star, 5000 posts Old School Fool Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 448  
Subject: Briefing.com View Date: 2/2/2005 2:52 AM
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Recommendations: 3
http://snipurl.com/ch22

Boston Scientific's 4Q04 (Dec) results were somewhat anticlimactic considering the medical device maker preannounced sales on January 11, but they were still a positive confirmation of the company's growth. EPS soared 188% to $0.49 (consensus of $0.48) thanks to the contribution of its drug-eluting stent. Taxus was not introduced until late 1Q04 (Mar), so Boston Scientific benefited from easy comparisons.

...

Although growth rates in 2005 will undoubtedly slow (particularly as the company laps its Taxus introduction), Wall Street projections still call for 34% in EPS growth and 17% in revenue growth. The REALITY trial, scheduled to be released in March, should help maintain Taxus' 65-70% market share as it pits Taxus against Johnson & Johnson's (JNJ) Cypher. Previous studies have demonstrated Taxus' better restenosis rate (which measures the rate of artery reblocking). Finally, the follow-up drug-eluting stent to Taxus contines to progress through development with enrollment scheduled to end this year and approval for mid-2006.

Trading at a low 15.4x estimated FY05 earnings (a noticeable discount to peers and the S&P 500), BSX is arguably undervalued considering its growth prospects and high rate of cash generation. Growth-oriented investors should consider adding positions to BSX as a leveraged play on the medical device space.
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next

Announcements

Pencils of Promise - Back to School Drive
"Pencils of Promise works with communities across the globe to build schools and create programs that provide education opportunities for children."
Post of the Day:
Value Hounds

Netflix Riles Investors
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement